 |
|
|
| |
DolPHIN-1: Dolutegravir vs Efavirenz when Initiating Treatment in Late Pregnancy
|
| |
| |
Reported by Jules Levin
CROI 2018 March 4-7 Boston, MA
Waitt CJ1,2, Walimbwa SI2, Orrell C3, Lamorde M2, Heiberg C3, Mehta U4, KabogozzaJP2, Coombs JA3, ByamugishaJ5, Gini J1, Kintu K2, Amara A1, MalabaT4, Else LJ1, Myer L4, Khoo SH1for the DolPHIN-1 Study Group
1Department of Molecular and Clinical Pharmacology, University of Liverpool, UK 2 Infectious Diseases Institute, MakerereUniversity College of Health Sciences, Uganda 3 Desmond Tutu HIV Foundation, Cape Town, South Africa
4 University of Cape Town, South Africa 5 Department of Obstetrics and Gynaecology, Makerere University College of Health Sciences, Kampala, Uganda
|
| |
|
|
|
|
|
